Regenxbio Inc. (RGNX) Hits New 1-Year Low at $7.58
Regenxbio Inc. (NASDAQ:RGNX) hit a new 52-week low during trading on Wednesday . The stock traded as low as $7.58 and last traded at $7.65, with a volume of 113,535 shares. The stock had previously closed at $7.98.
Several equities research analysts recently commented on RGNX shares. Zacks Investment Research cut Regenxbio from a “hold” rating to a “sell” rating in a report on Tuesday, March 22nd. Morgan Stanley boosted their target price on Regenxbio from $34.00 to $36.00 in a report on Friday, April 8th. Chardan Capital reissued a “buy” rating on shares of Regenxbio in a report on Tuesday, May 10th. Finally, Piper Jaffray Cos. reissued a “buy” rating and set a $33.00 target price on shares of Regenxbio in a report on Tuesday, July 5th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $28.35.
The stock’s 50-day moving average is $10.27 and its 200-day moving average is $11.88. The company’s market cap is $199.91 million.
Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by $0.01. Equities analysts forecast that Regenxbio Inc. will post ($2.37) EPS for the current fiscal year.
In other Regenxbio news, insider Fmr Llc sold 18,300 shares of the company’s stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $12.41, for a total transaction of $227,103.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.